Patient centricity describes the approach of designing research, development, and care in a way that systematically takes the needs, preferences, life realities, and values of patients into account. In clinical development, this means that studies are not just planned “for” patients, but with them—through structured involvement in protocol design, endpoint selection, information materials, and the design of procedures.
For sponsors and CROs, patient centricity is an operational quality principle. It can improve recruitment and retention, reduce protocol deviations, increase the acceptance of study measures, and strengthen the relevance of results for benefit assessments and healthcare decisions. At the same time, it requires clear processes so that patient-related inputs are collected, evaluated, and documented in a traceable manner.
Benefits and Relevance for Clinical Trials
Many trials encounter practical hurdles: high burden from visits, complicated logistics, long questionnaires, or unclear informed consent. Patient centricity aims to reduce unnecessary burden without compromising scientific and regulatory requirements. When participants understand why measures are necessary and when the study schedule fits into their daily lives, dropout rates decrease and data completeness increases.
Another driver is the relevance of results. In addition to classic clinical endpoints, patient-reported outcomes (PROs) and other patient-relevant endpoints are gaining importance. They capture symptoms, functional capacity, and quality of life, supplementing laboratory or imaging parameters with the perspective of those affected. This is particularly important when evidence later flows into HTA processes and reimbursement decisions.
Concrete Building Blocks of Patient-Centric Trial Planning
Patient centricity can be translated into concrete building blocks: early involvement of patient groups, understandable information (plain language), realistic visit schedules, minimization of redundant assessments, flexible appointment windows, and support for travel or childcare costs. Digital instruments such as eConsent, ePRO, or tele-visits can provide additional help, provided they are validated and implemented in an accessible manner.
The alignment between patient benefit and data integrity is crucial. An electronic diary can facilitate data collection but requires validation, training, and a concept for system failures. For decentralized elements, data protection, roles (e.g., home health nurse), and responsibilities must be clearly defined. The burden on sites must also not be underestimated: patient-friendly concepts only work if centers and support teams can sustain them operationally.
Involvement of Patients: Methods and Documentation
Patient input can be collected via advisory boards, interviews, focus groups, surveys, or co-creation workshops. It is crucial to design participation so that it is representative and targeted. In rare diseases, patient organizations often play a key role, while in common indications, digital panels can also be used. In pediatric indications, parent or caregiver perspectives are often added.
To make patient centricity auditable, inputs should be documented in a structured manner: What questions were asked, which groups were involved, what recommendations were derived, and how were decisions justified? This traceability is important when patient-related adjustments must later be explained to regulators, ethics committees, or internal stakeholders. A practical approach is a “decision log” structure that links inputs, evaluation, decision, and implementation steps.
Regulatory Perspective in the EU and Germany
From a regulatory perspective, patient centricity is closely linked to the protection of participants and the quality of informed consent. Good Clinical Practice principles emphasize understandable information, appropriate risk-benefit assessment, and respectful treatment of participants. In the EU, the EU Clinical Trials Regulation (Regulation (EU) No 536/2014) strengthens transparency and patient safety, thus acting as a framework for patient-oriented processes, particularly regarding information, consent, and safety management.
For medical devices, patient centricity becomes indirectly relevant when clinical evaluations and post-market clinical follow-up consider patient-relevant endpoints. Under the EU Medical Device Regulation (Regulation (EU) 2017/745), clinical evidence must be planned throughout the product lifecycle, which includes patient-related benefit aspects. Data protection (GDPR) and requirements for understandable communication also play a role, e.g., in digital data collection.
Implementation in the Sponsor-CRO Setup and Measuring Success
For sponsors, the question arises as to how patient centricity is anchored in the project: roles, responsibilities, budget, schedule, and quality management must be defined. It is often useful to integrate patient-centric requirements into the protocol and operationalization steps instead of treating them as a separate activity. CROs provide support in translating these into operational processes, e.g., adapting visit schedules, selecting PRO instruments, implementing ePRO systems, training centers, and establishing support structures.
Typical pitfalls include late involvement, unclear success criteria, insufficient consideration of diversity, and digital exclusion. Furthermore, patient-friendly measures can create unintended bias if only certain groups have access to digital tools. Therefore, alternatives (e.g., paper-based options) and clear documentation of the trade-offs are required.
Patient centricity should be measurable. Practical KPIs include recruitment duration, screen failure rate, retention, number and type of protocol deviations, data completeness for PROs, and participant feedback. The workload for sites can also decrease if processes are clear, materials are understandable, and support structures are established.
In the long term, patient centricity strengthens trust and acceptance of clinical research. It helps ensure that evidence is not only statistically significant but also relevant to those affected and implementable in healthcare—especially when trial results later flow into benefit assessments, guidelines, or reimbursement decisions.
FAQ: Does patient centricity always mean decentralized trials?
No. Decentralized elements are one possible instrument, but patient centricity can also be achieved through better information, realistic visit schedules, or the choice of patient-relevant endpoints.
FAQ: How can patient centricity be practically demonstrated?
Through documented involvement (e.g., protocol feedback), traceable design decisions, and measurable improvements such as higher retention or better PRO data completeness.
FAQ: What role do PROs play?
Patient-reported outcomes are a core component for systematically capturing symptoms and quality of life and for quantifying patient-relevant benefit aspects.
Regulatory references (selection):
- ICH E6(R3) Good Clinical Practice – Protection of participants and quality of processes
- Regulation (EU) No 536/2014 (Clinical Trials Regulation) – Transparency and patient safety in clinical trials
- Regulation (EU) 2017/745 (Medical Device Regulation) – Clinical evidence and lifecycle approach
- EU GDPR (2016/679) – Data protection for health data and digital collection